CA2059865A1 - Compositions pharmaceutiques contenant des glycosaminoglycans absorbables par voie orale - Google Patents

Compositions pharmaceutiques contenant des glycosaminoglycans absorbables par voie orale

Info

Publication number
CA2059865A1
CA2059865A1 CA2059865A CA2059865A CA2059865A1 CA 2059865 A1 CA2059865 A1 CA 2059865A1 CA 2059865 A CA2059865 A CA 2059865A CA 2059865 A CA2059865 A CA 2059865A CA 2059865 A1 CA2059865 A1 CA 2059865A1
Authority
CA
Canada
Prior art keywords
glycosaminoglycans
pharmaceutical compositions
compositions containing
containing orally
orally absorbable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2059865A
Other languages
English (en)
Other versions
CA2059865C (fr
Inventor
Manlio Cristofori
Egidio Marchi
Leone G. Rotini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfa Wasserman SpA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2059865A1 publication Critical patent/CA2059865A1/fr
Application granted granted Critical
Publication of CA2059865C publication Critical patent/CA2059865C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002059865A 1991-01-30 1992-01-22 Compositions pharmaceutiques contenant des glycosaminoglycans absorbables par voie orale Expired - Lifetime CA2059865C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITBO910024A IT1245761B (it) 1991-01-30 1991-01-30 Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
ITB091A000024 1991-01-30

Publications (2)

Publication Number Publication Date
CA2059865A1 true CA2059865A1 (fr) 1992-07-31
CA2059865C CA2059865C (fr) 1999-01-26

Family

ID=11337212

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002059865A Expired - Lifetime CA2059865C (fr) 1991-01-30 1992-01-22 Compositions pharmaceutiques contenant des glycosaminoglycans absorbables par voie orale

Country Status (8)

Country Link
US (1) US5252339A (fr)
EP (1) EP0497162B1 (fr)
JP (1) JPH0755907B2 (fr)
KR (1) KR100210359B1 (fr)
CA (1) CA2059865C (fr)
DE (1) DE69212608T2 (fr)
ES (1) ES2090368T3 (fr)
IT (1) IT1245761B (fr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1256236B (it) * 1992-12-23 1995-11-29 Mediolanum Farmaceutici Srl Oligosaccaridi aventi attivita' biologica e procedimento per la loro preparazione di glicosaminoglicani
IT1270846B (it) * 1993-05-10 1997-05-13 Alfa Wassermann Spa Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica.
DE69429576T2 (de) * 1993-09-30 2002-08-22 Seikagaku Kogyo K.K., Tokio/Tokyo Dermatansulfatezusammensetzung als antithromotisches mittel
US5888984A (en) * 1994-05-12 1999-03-30 Dermal Research Laboratories, Inc. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
DE19501266A1 (de) * 1995-01-18 1996-07-25 Madaus Ag Verfahren zur Herstellung von Flavano-Lignan-Zubereitungen mit verbesserter Freisetzung und Resorbierbarkeit danach erhältliche Zubereitungen und deren Verwendung zur Herstellung von Arzneimitteln
US6262255B1 (en) 1995-04-05 2001-07-17 Biomm, Inc. Non-immunogenic, biocompatible macromolecular membrane compositions, and methods for making them
GB2305604B (en) * 1995-09-29 1999-06-23 Quest Vitamins Ltd Carrier base material
CA2235223A1 (fr) 1995-10-30 1997-05-09 Massachusetts Institute Of Technology Lyases de polysaccharides designees rationnellement derivees de l'heparinase i
IT1285546B1 (it) * 1996-01-16 1998-06-18 Alfa Wassermann Spa Uso del dermatano solfato a basso peso molecolare e delle specialita' medicinali che lo contengono nella terapia e nella prevenzione della
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US6645948B2 (en) 1998-03-24 2003-11-11 George D. Petito Nutritional composition for the treatment of connective tissue
US7691829B2 (en) * 1998-03-24 2010-04-06 Petito George D Composition and method for healing tissues
US6476005B1 (en) 1998-03-24 2002-11-05 George D. Petito Oral and injectable nutritional composition
US20050208114A1 (en) * 1998-03-24 2005-09-22 Petito George D Composition and method for healing tissues
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
EP1109919A2 (fr) * 1998-08-27 2001-06-27 Massachusetts Institute Of Technology Heparinases a conception rationnelle derivees de l'heparinase i et ii
IL127826A0 (en) * 1998-12-29 1999-10-28 Laster Gail Restenosis drug therapy
IL127896A0 (en) * 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
AU2745700A (en) 1999-02-01 2000-08-18 Dermal Research Laboratories, Inc. A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
CA2363123C (fr) * 1999-02-22 2011-09-06 Kenneth Iain Cumming Dose orale solide contenant un agent de potentialisation
JP4824170B2 (ja) * 1999-04-23 2011-11-30 マサチューセッツ インスティテュート オブ テクノロジー ポリマーを表記するためのシステムおよび方法
US6458383B2 (en) * 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
JP2003504428A (ja) * 1999-06-30 2003-02-04 ハミルトン シビック ホスピタルズ リサーチ ディベロップメント インコーポレイテッド クロット関連凝固因子を阻害するヘパリン組成物
WO2001066772A2 (fr) * 2000-03-08 2001-09-13 Massachusetts Institute Of Technology Heparinase iii et ses utilisations
US7259152B2 (en) * 2000-06-07 2007-08-21 Alfa Wasserman, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
AU2001291549A1 (en) * 2000-09-08 2002-03-22 Hamilton Civic Hospitals Research Development Inc. Antithrombotic compositions
DE60138115D1 (de) 2000-09-12 2009-05-07 Massachusetts Inst Technology Verfahren und produkte, die mit niedermolekularem heparin assoziiert sind
US7709461B2 (en) 2000-10-18 2010-05-04 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
EP1390048A2 (fr) * 2001-02-16 2004-02-25 Shimizu Pharmaceutical Co., Ltd. Preparation contenant un mucopolysaccharide et son procede de production
DE60211494T2 (de) * 2001-03-26 2006-10-12 Novartis Ag Pharmazeutische zusammensetzung enthaltend ein schlecht wasserlösliches staurosporin, eine oberflächenaktive substanz und ein wasserlösliches polymer
BRPI0101486B1 (pt) * 2001-04-17 2017-09-19 Cristália Produtos Químicos Farmacêuticos Ltda. Pharmaceutical composition for topic use containing heparin for the treatment of skin or mucosal injuries caused by burns
WO2002089820A1 (fr) * 2001-05-09 2002-11-14 Mediplex Corporation Formulation de derives d'heparine amphiphiles servant a ameliorer l'absorption par les muqueuses
EP1390383B1 (fr) 2001-05-11 2012-02-29 Isis Pharmaceuticals, Inc. Renforcateurs de permeation antisens
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US20030013680A1 (en) * 2001-06-12 2003-01-16 Keryx Methods using glycosaminoglycans for the treatment of nephropathy
US20030228368A1 (en) * 2001-09-28 2003-12-11 David Wynn Edible solid composition and dosage form
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
EP2112920B1 (fr) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
US20060004098A1 (en) * 2003-07-28 2006-01-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds useful for treating neurological disorders
US20050181047A1 (en) * 2004-02-18 2005-08-18 Jaime Romero Compositions and methods for timed release of water-soluble nutritional supplements
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
WO2006015171A2 (fr) * 2004-07-28 2006-02-09 The Texas A & M University System Utilisation de glycosaminoglycannes pour la prevention et le traitement de sepsie
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
JP2006298791A (ja) * 2005-04-18 2006-11-02 Kotobuki Seiyaku Kk グリコサミノグリカン又はその塩を含む経口投与用医薬品、健康食品又は栄養薬品組成物。
US8298602B2 (en) * 2005-10-11 2012-10-30 Purecircle Sdn Bhd Process for manufacturing a sweetener and use thereof
JP5324223B2 (ja) 2005-12-08 2013-10-23 トランセイブ， インク． 肺感染症を治療する抗感染薬の脂質ベースの組成物及びその使用法
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007112581A1 (fr) 2006-04-03 2007-10-11 Isa Odidi Dispositif d'administration à libération commandée comprenant un enrobage organosol
WO2007117550A2 (fr) * 2006-04-06 2007-10-18 Transave, Inc. Procédés d'encapsulation liposomale induite par coacervation et formulations associées
WO2007117706A2 (fr) 2006-04-07 2007-10-18 Merrion Research Iii Limited Forme pharmaceutique solide par voie orale contenant un activateur
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
CN102046192B (zh) 2008-05-07 2014-11-19 默里昂研究Ⅲ有限公司 GnRH相关化合物的组合物及制备方法
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
EP2525783A1 (fr) * 2010-01-18 2012-11-28 Cephalon France Lyophilisats oraux améliorés contenant un copolymère de pvp/va
WO2011120033A1 (fr) 2010-03-26 2011-09-29 Merrion Research Iii Limited Compositions pharmaceutiques d'inhibiteurs de facteur xa sélectifs destinées à une administration orale
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2012094598A2 (fr) 2011-01-07 2012-07-12 Merrion Research Iii Limited Compositions pharmaceutiques de fer pour administration orale
WO2013151727A1 (fr) 2012-04-03 2013-10-10 Smith Medical Asd, Inc. Compositions d'agents de charge d'héparine et procédés associés
PL2852391T3 (pl) 2012-05-21 2022-04-11 Insmed Incorporated Układy do leczenia infekcji płuc
MX2015006681A (es) 2012-11-29 2016-04-06 Insmed Inc Formulaciones de vancomicina estabilizadas.
SMT202000516T1 (it) 2014-05-15 2020-11-10 Insmed Inc Metodi per trattamento di infezioni micobatteriche polmonati non tubercolari
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
WO2019191627A1 (fr) 2018-03-30 2019-10-03 Insmed Incorporated Procédés pour la fabrication continue de produits médicamenteux liposomaux
WO2019213398A1 (fr) 2018-05-02 2019-11-07 Insmed Incorporated Procédés de fabrication de formulations de médicament liposomal
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3548052A (en) * 1964-10-27 1970-12-15 Canada Packers Ltd Heparin compositions and methods of using same
US3482014A (en) * 1966-06-29 1969-12-02 Canada Packers Ltd Orally active heparin and method for making and using same
US3506642A (en) * 1967-07-03 1970-04-14 Canada Packers Ltd Stable orally active heparinoid complexes
US3574832A (en) * 1968-05-29 1971-04-13 American Cyanamid Co Therapeutic heparin-surfactant compositions
US3577534A (en) * 1968-06-20 1971-05-04 Canada Packers Ltd Stable orally active heparinoid complexes
IT1062779B (it) * 1974-04-04 1985-01-14 Crinos Industria Farmaco Composizione farmaceutica contenente un fattore eparinoidico
IT1069492B (it) * 1976-10-13 1985-03-25 Alfa Farmaceutici Spa Composizione farmaceutica sommini stratrice per via orale contenente un fattore eparinoide sospeso in un veicolo oleoso costituito da triace tato di glicerina
GB1591306A (en) * 1976-10-23 1981-06-17 Choay Sa Liposomes containing heparin and a process for obtaining them
FR2492259A1 (fr) * 1980-10-21 1982-04-23 Idinvex Sa Formulation d'heparine
US4654327A (en) * 1982-04-21 1987-03-31 Research Corp. Quaternary ammonium complexes of heparin
US4604376A (en) * 1982-04-21 1986-08-05 Research Corporation Enteric compounds and complexes
US4510135A (en) * 1982-04-21 1985-04-09 Research Corporation Orally administered heparin
CH656533A5 (de) * 1982-12-10 1986-07-15 Sandoz Ag Therapeutisches praeparat enthaltend hydrierte ergotalkaloide und niedermolekulares heparin.
DE3331009A1 (de) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
JPS6054313A (ja) * 1983-09-01 1985-03-28 Terumo Corp 腸管吸収性ヘパリン組成物
JPS61502192A (ja) * 1984-05-21 1986-10-02 ボ−ダ−，ニコラス・エス 経口活性ヘパリン多重体
US5102788A (en) * 1988-11-21 1992-04-07 Hygeia Sciences, Inc. Immunoassay including lyophilized reactant mixture
US5032405A (en) * 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents

Also Published As

Publication number Publication date
ES2090368T3 (es) 1996-10-16
JPH0543471A (ja) 1993-02-23
IT1245761B (it) 1994-10-14
JPH0755907B2 (ja) 1995-06-14
ITBO910024A1 (it) 1992-07-30
EP0497162B1 (fr) 1996-08-07
CA2059865C (fr) 1999-01-26
KR100210359B1 (ko) 1999-07-15
DE69212608D1 (de) 1996-09-12
US5252339A (en) 1993-10-12
EP0497162A1 (fr) 1992-08-05
ITBO910024A0 (it) 1991-01-30
DE69212608T2 (de) 1996-11-28
KR920014467A (ko) 1992-08-25

Similar Documents

Publication Publication Date Title
IT1245761B (it) Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
CA2065809A1 (fr) Formulations pharmaceutiques gastroresistantes pour administration par voie orale et contenant des sels d'acides biliaires
IE831799L (en) Controlled release naproxen and naproxen sodium tablets.
CA2186039A1 (fr) Nouvelle forme galenique pharmaceutique orale
CA2065773A1 (fr) Formulations pharmaceutiques gastroresistantes pour administration par voie orale et contenant des acides biliaires
CA2221356A1 (fr) Traitement d'affections intestinales inflammatoires a l'aide de formes galeniques orales d'acides omega-3 polyinsatures
CA2009593A1 (fr) Medicament contenant de l'acide dihydrolipoique comme ingredient actif
CA2093806A1 (fr) Methode de traitement ou de prevention du diabete de type 1 par l'administration orale d'insuline
CA2070061A1 (fr) Composition pharmaceutique renfermant des polypeptides physiologiquement actives
CA2004239A1 (fr) Utilisation de l'acetyl-d-carnitine dans le traitement therapeutique du glaucome et composes pharmaceutiques utiles dans un tel traitement
CA2106172A1 (fr) Utilisation de l'acide 2-(3,4-dimethoxycinnamoyl)aminobenzoique pour le traitement de la restenose associee aux interventions coronariennes
CA2024916A1 (fr) Medicaments pour les troubles respiratoires comprenant le salmeterol et le propionate fluticasone
UA41995C2 (uk) Лікарська форма азитроміцину з контрольованим вивільненням ( варіанти ), спосіб її введення, спосіб її виготовлення і спосіб лікування інфекційних захворювань ссавців з її використанням ( варіанти )
CA2021574A1 (fr) Preparation pharmaceutique a fragmentation rapide, au gout desagreable masque, pour administration par voie buccale
CA2289717A1 (fr) Nouveau traitement de la constipation
CA2166483A1 (fr) Nouvelle formulation pharmaceutique
IE881916L (en) Press-coated dihydropyridine tablets
AU2584192A (en) Bone-growth-stimulating composition
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
CA2192899A1 (fr) Composition contenant de la l-carnitine et de l'acide hydroxycitrique
CA2065652A1 (fr) Formulations pharmaceutiques gastro-intestinales a liberation controlee pour administration orale contenant des acides biliaires et leurs sels
CA2170748A1 (fr) Preparations pharmaceutiques pour le traitement cible de la maladie de crohn et de la colite ulcereuse
CA2024872A1 (fr) Medicaments
EP0375628A3 (fr) Utilisation de l'acétyle-L-carnitine pour le traitement de la cataracte et compositions pharmaceutiques utilisables pour ce traitement

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry